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Introduction
The region of the foramen magnum (FM) presents an especially difficult area for therapeutic intervention. Indeed, this location is challenging to access surgically, particularly in the case of intramedullary and anterior lesions (1) (2) (3) (4) (5) (6) (7) . Furthermore, the eloquent nature of the tissue circumscribed within the FM leaves any treatment modality open to potentially treacherous and uncertain results (3, 5, 8, 9) . Therefore, the potential for morbidity associated with therapy to the foramen magnum, most frequently in the form of lower cranial nerve deficits, has encouraged the search for methods that can effectively treat lesions of this region while sparing the important neighboring structures (2, (5) (6) (7) (10) (11) (12) . Certain surgical operations, in particular the far lateral transcondylar approach, present a safe means of attacking lesions of the foramen magnum, but there is a cost involved (1, 2, 5, (13) (14) (15) . These are very complicated procedures that require an experienced surgeon, and the operation itself is a major undertaking (2, 5, 15) . Perhaps most importantly, the transcondylar approach along with other accepted operations are often limited to the treatment and excision of extra-axial lesions (1, 13, 14) .
To date, the benefits of stereotactic radiosurgery for FM lesions have not been sufficiently assessed, due to the fact that a low number of cases have undergone radiosurgical treatment (16) . These cases also tend to be buried in larger radiosurgical case series so the specifics of the treatment delivered to the foramen magnum lesions are not documented (17, 18) . Moreover, the few cases that have been reported in the literature deal almost exclusively with meningiomas, so the efficacy of radiosurgical intervention in the case of other tumor types is essentially unknown (16, 17) . Thus, there is a clear need for a large-scale study that assesses the viability of radiosurgery for lesions of the foramen magnum.
Image-guided robotic radiosurgery known as the CyberKnife system (Accuray, Inc., Sunnyvale, CA) was introduced at Stanford University Medical Center in 1994 (19-25). Since 1999, 35 patients with lesions that either span or approximate the FM were treated at our institution. These patients presented with a wide variety of both benign and malignant tumors. This report represents the largest and most diverse study of lesions involving the foramen magnum to date. Our objective was twofold: (i) to assess the safety and efficacy of CyberKnife treatment for lesions involving the FM; and (ii) to document the treatment dosimetries used for these lesions, thereby establishing a basis for the future radiosurgical treatment of FM lesions in treatment centers other than our own.
Patients and Methods
A retrospective analysis was performed on 35 patients that were treated at Stanford University Medical Center from 1999 to 2004. The demographics of the patient population in this study are included in Table I . A multidisciplinary team of specialists that included neurosurgeons, radiation oncologists, and neuroradiologists was involved in evaluating all patients. After signing an institutional-review board consent form, the image-guided CyberKnife radiosurgical system was used to administer radiosurgery to the region of the FM in every case. The CyberKnife system has been described previously by Adler et al. (21) , and the details of treatment planning and delivery can be found in previous studies (20, 26, 27) . All patients were given Zofran and Decadron following the procedure, and all of the procedures were performed on an outpatient basis.
Medical records of each patient were examined and data collected regarding clinical presentation, tumor location and histology, indications for treatment, prior medical and/or surgical treatments, and complications. In addition, phone interviews were conducted with 27 patients or their relatives as a means of acquiring long-term follow-up data.
We defined a FM lesion as any mass that spanned the basionopisthion (B-O) line, also known as McRae's Line, from either above or below (n=23). Near foramen magnum lesions (nFM) were defined as any mass within 1 cm of the B-O line, which also had a significant isodose line traversing the FM (n=12). Representative examples of CyberKnife treatment plans of FM and nFM can be seen in Figure 1 . The majority of patients presented with at least one clinical sign and/or 
*Early denotes a planned radiosurgical procedure within one month of surgical resection. **Late denotes a radiosurgical procedure due to recurrence or increased tumor growth performed greater than one month after the initial surgery symptom (n=27), though a sizeable number of patients were asymptomatic and had their lesions found incidentally (n=8) ( Table II) . Histologies were determined either by prior surgery or radiographic criteria and included 25 benign tumors (nine meningiomas, five schwannomas, four neurofibromas, three hemangioblastomas, two ependymomas, one chordomas, and one pilocytic astrocytoma) along with 10 malignant growths (nine metastases and one chondrosarcoma) (Tables  III & IV) . The CyberKnife radiosurgical system was utilized for all patients, and the specific settings used in the treatment of each individual lesion were recorded (Tables III & IV) .
Results
Thirty-five patients (17 men, 18 women; mean age, 51 yr; range, 18-83) with 35 lesions either spanning or approximating the foramen magnum were treated with the CyberKnife radiosurgical system (Table I) . Presenting signs and symptoms varied depending on the location of the lesion (Table II) .
The specific fractionation schedule (mean of two sessions; range, 1-5) was based on the size of the treated lesion (Tables  III & IV) . In those patients with benign lesions of the FM, the largest tumor volumes came from our schwannoma and chordoma series (Table III) .
Radiographic follow-up was obtained for twenty-three (66%) patients (Table V) . The mean time for follow-up for imaging was 15.4 months (range 2 to 48 months). Using radiographic assessments of tumor volume, nine of the twentythree (39%) were stable in size, ten lesions decreased in size (43%), and four lesions increased in size (17%). Therefore, nineteen (83%) patients experienced either stabilization or regression of their lesion.
In terms of symptom relief, follow-up was collected for twenty-four (69%) patients (Table V) . The mean time for symptom relief follow-up symptom as assessed by formal clinic visit with neurologic examination was 8.9 months (range 2 to 24 months). Eleven (46%) of these patients experienced no change in their signs or symptoms, while seven (29%) patients experienced improvement. Six (25%) patients witnessed deterioration in their signs and symptoms. Overall, eighteen (75%) patients had their signs and symptoms either stabilize or improve.
There were eleven (31%) deaths in our series, eight of which were related to the disease (though not directly related to CyberKnife treatment) and three of which were from unrelated causes (Table V) .
Through phone interviews, we were able to assess patient satisfaction with the CyberKnife experience in fifteen patients (Table V) . The survey was conducted on average 32.4 months post treatment (range 9 to 76 months). Patients were asked to weigh their satisfaction on a subjective scale of 1-10, with 10 representing complete satisfaction and a willingness to undergo treatment again, while a 1 represented utter dissatisfaction and a refusal to undergo treatment again. The average rating among the patients was 8.6, and fourteen (93%) of these patients would elect to have CyberKnife again if presented with the same medical circumstances.
Complications directly related to CyberKnife radiosurgery were noted in four (11%) of the thirty-five patients (Table  VI) . These included one case of temporary emesis immediately following treatment, one case of cystic enlargement two months out, and two cases of radiation necrosis (occurring 1.5 years and 2.5 years out from treatment). In one case of radiation necrosis, the patients underwent surgical treatment; in the case of cystic enlargement, surgery was subsequently performed as well.
Discussion
CyberKnife treatment has proven especially useful in the treatment of tumors that are difficult to access surgically (20, 26, (28) (29) (30) (31) (32) , giving rise to a growing interest in the use of CyberKnife for such lesions. This minimally invasive radiosurgical approach is also becoming a viable treatment modality for tumors that involve eloquent areas of the neuraxis. Due to the large degree of freedom provided by the frameless image-guided robotic arm, CyberKnife can be used to treat lesions that other radiosurgical devices may have difficulty targeting (23, 24, 33) .
CyberKnife and the Foramen Magnum
To date, the efficacy of CyberKnife in the treatment of lesions involving the foramen magnum has yet to be firmly established. Our study attempts to redress this deficit, as it includes the largest number of documented cases. There are two fundamental reasons that our interest was drawn to the foramen magnum: (i) it is a relatively frequent location of tumors and (ii) the area is associated with critically eloquent tissue. A study of lesions involving this area is, therefore, long overdue. Several papers analyze the effect of radiosurgery on the foramen magnum, while other studies only consider lesions of the foramen magnum within the broader context of microsurgery (10, 11, (16) (17) (18) . These radiosurgical reports fail to describe the specific treatment delivered to the foramen magnum, so any practical lessons and therapeutic regimens are lost.
Our study represents a detailed analysis of radiosurgery for the foramen magnum. We have included a broad range of histologies, as well as extra-axial bony lesions for which radiosurgical treatment plays a more important role.
CyberKnife vs. Conventional Surgery
CyberKnife easily targets complex lesions of the foramen magnum while minimizing exposure of the cervico-medullary junction to radiation. This is especially important in elderly patients and in other patients with complex medical problems in which surgery would be ill-advised. Technical advancements have been made in terms of surgical technique, including microsurgical approaches and image guidance, both of which have reduced morbidity associated with operating (3, 5-7, 10, 11, 13, 15, 34, 35) . However, there is still significant morbidity and mortality associated with surgery in the foramen magnum (9, 12, 13, 15, 34, 35) . Radiosurgical treatment of lesions (especially malignant tumors) is not without potential morbidities, for instance the edema and inflammation that may stem from radiation necrosis. The potential for edema from radiation necrosis would be a potential drawback for using radiosurgery in the FM considering that no decompression is performed. We did not observe a significant amount of radiation necrosis in our series. In fact, in our series the complication rate was very low (11%), which compares favorably with surgical intervention. This is certainly encouraging when one considers that more patients are demanding less invasive procedures. 
CyberKnife vs. Other Radiosurgical Modalities
In our study, eight (23%) patients had lesions that extended as far as C2. Due to the restrictions of frame-based treatments, these lesions would have proven inaccessible to systems based on rigid fixation. Furthermore, this fixation within the frame of the makes hypofractionation very inconvenient, forcing most treatments to be conducted in a single setting. In our study, nineteen (54%) patients were treated with multiple sessions on different days. There are theoretical radiobiological advantages to fractionation for nearby normal structures relative to the treated lesion (25, 26). However, whether or not this theoretical advantage confers a true clinical benefit remains to be seen. Tumor control is generally equivalent in lesions treated with either modality.
Patient Satisfaction
Through our phone interviews, we were able to acquire information regarding patient satisfaction for the CyberKnife procedure. Admittedly, patient satisfaction data has inherent biases. For instance, surviving patients tend to have mostly benign lesions and are more likely to perceive their treatment experience favorably. Despite these biases, this data has great potential value and reflects the growing consensus among patients that minimally invasive procedures performed on an outpatient basis are preferable to the long hospital stays and grueling recovery times often associated with major surgical operations.
